152 related articles for article (PubMed ID: 22399596)
21. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes.
Chen H; Wu S
Chin Med J (Engl); 2002 Jul; 115(7):987-90. PubMed ID: 12150726
[TBL] [Abstract][Full Text] [Related]
22. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
[TBL] [Abstract][Full Text] [Related]
23. A selective activity of DNMTi decitabine on AML1ETO positive cells?
Santini V
Leuk Res; 2007 Jun; 31(6):741-2. PubMed ID: 17240447
[No Abstract] [Full Text] [Related]
24. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Silverman LR
Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
[TBL] [Abstract][Full Text] [Related]
25. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Santini V
Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
[TBL] [Abstract][Full Text] [Related]
26. Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes.
Yang Y; Li J; Geng Y; Liu L; Li D
J Clin Lab Anal; 2021 Feb; 35(2):e23597. PubMed ID: 33080073
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol Suppresses Growth and Migration of Myelodysplastic Cells by Inhibiting the Expression of Elevated Cyclin D1 (CCND1).
Zhou W; Xu S; Ying Y; Zhou R; Chen X
DNA Cell Biol; 2017 Nov; 36(11):966-975. PubMed ID: 29035583
[TBL] [Abstract][Full Text] [Related]
28. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
Demakos EP; Linebaugh JA
Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
[TBL] [Abstract][Full Text] [Related]
29. Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Guo Y; Liu Z; Duan L; Shen H; Ding K; Fu R
Invest New Drugs; 2022 Aug; 40(4):738-746. PubMed ID: 35576022
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Hofmann WK; Takeuchi S; Takeuchi N; Thiel E; Hoelzer D; Koeffler HP
Leuk Res; 2006 Nov; 30(11):1347-53. PubMed ID: 16682076
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic therapy in myelodysplastic syndromes.
Musolino C; Sant'antonio E; Penna G; Alonci A; Russo S; Granata A; Allegra A
Eur J Haematol; 2010 Jun; 84(6):463-73. PubMed ID: 20192987
[TBL] [Abstract][Full Text] [Related]
32. Silencing HO-1 sensitizes SKM-1 cells to apoptosis induced by low concentration 5-azacytidine through enhancing p16 demethylation.
Wang P; Ma D; Wang J; Fang Q; Gao R; Wu W; Lu T; Cao L
Int J Oncol; 2015 Mar; 46(3):1317-27. PubMed ID: 25585641
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes.
Zou J; Zhou Z; Wan L; Tong Y; Qin Y; Wang C; Zhou K
PLoS One; 2015; 10(8):e0136843. PubMed ID: 26317501
[TBL] [Abstract][Full Text] [Related]
34. [p15(INK4B) methylation on prognosis and response to decitabine in patients with MDS].
Zhang Y; Song LX; Wu LY; Chang CK; Li X
Zhonghua Xue Ye Xue Za Zhi; 2013 Mar; 34(3):237-41. PubMed ID: 23683424
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.
Gao XN; Lin J; Li YH; Gao L; Wang XR; Wang W; Kang HY; Yan GT; Wang LL; Yu L
Oncogene; 2011 Aug; 30(31):3416-28. PubMed ID: 21399664
[TBL] [Abstract][Full Text] [Related]
36. The role of azacitidine in the treatment of myelodysplastic syndromes.
Abdulhaq H; Rossetti JM
Expert Opin Investig Drugs; 2007 Dec; 16(12):1967-75. PubMed ID: 18042004
[TBL] [Abstract][Full Text] [Related]
37. Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes.
Bontkes HJ; Ruben JM; Alhan C; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Leuk Res; 2012 Jul; 36(7):921-30. PubMed ID: 22503132
[TBL] [Abstract][Full Text] [Related]
38. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K
Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244
[TBL] [Abstract][Full Text] [Related]
39. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
Martín I; Navarro B; Serrano A; Villamón E; Calabuig M; Solano C; Chaves FJ; Yagüe N; Orts M; Amat P; Fuentes A; Seda E; García F; Hernández-Boluda JC; Tormo M
Ann Hematol; 2020 Mar; 99(3):527-537. PubMed ID: 31989250
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
Takahashi Y; Kimura S; Okano M
Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
